| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC1084 |
| Trial ID | CTIS2022-502907-31-00 |
| Disease | Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | KTE-X19|Tecartus|Brexucabtagene autoleucel |
| Location approved | US, EU, UK, Australia, Canada |
| Generation | 2nd |
| Phase | Phase1 |
| Recruitment status | Not Recruiting |
| Title | A Phase II study evaluating efficacy of KTE-X19 CAR-T cell therapy in Relapsed or Refractory Mantle-Cell Lymphoma achieving a partial response during Ibrutinib salvage therapy |
| Year | 2022 |
| Country | Italy |
| Company sponsor | Fondazione IRCCS Istituto Nazionale Dei Tumori |
| Vector information | |||||
|
|||||
| Cohort 1 | |||||||
|
|||||||